Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis
Chemistry & Biodiversity · 2023
DOI: 10.1002/cbdv.202301093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Busra Dincer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Ondokuz Mayıs University, Samsun, 55100, Turkey. Hauptthemen laut MEDLINE: Paclitaxel, Acetamides, Receptor, Melatonin, MT1, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Research Fund of the Erzincan Binali Yıldırım University, Turkey.
Abstract (Originalsprache)
This study investigates the potential of agomelatine (AGO), a synthetic melatoninergic drug, in combination with paclitaxel (PTX) for the treatment of breast cancer. The effects of AGO, PTX and melatonin (MTN) on breast cancer cell viability were investigated, focusing on the role of MT1 receptors. Cell viability and gene expression were analyzed in MCF‐7 and MDA‐MB‐231 breast cancer cell experiments. The results show that AGO has cytotoxic effects on breast cancer cells similar to MTN. Combining AGO and MTN with PTX showed synergistic effects in MCF‐7 cells. The study also reveals differences in the molecular mechanisms of breast cancer between estrogen‐positive MCF‐7 cells and estrogen‐negative MDA‐MB‐231 cells. Combination with AGO and PTX affects apoptosis‐associated proteins in both cell types. The findings suggest that AGO, combined with PTX, may be a promising adjuvant therapy for breast cancer and highlight the importance of MTN receptors in its mechanism of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Ondokuz Mayıs University, Samsun, 55100, Turkey.
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, 24100, Turkey.
- Department of Pharmacology, Faculty of Medicine, Kastamonu University, Kastamonu, 37150, Turkey.
ORCID-Profile: Busra Dincer
Förderung
- Research Fund of the Erzincan Binali Yıldırım University, Turkey
Zitieren
APA
Dincer, B., Yildiztekin, G., & Cinar, I. (2023). Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202301093
Vancouver
Dincer B, Yildiztekin G, Cinar I. Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202301093
BibTeX
@article{Dincer2023,
author = {Dincer, Busra and Yildiztekin, Gizem and Cinar, Irfan},
title = {Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis},
journal = {Chemistry & Biodiversity},
year = {2023},
doi = {10.1002/cbdv.202301093}
}
EUVIMED